RedHill Biopharma (RDHL) Accumulated Expenses (2016 - 2025)

RedHill Biopharma (RDHL) has 10 years of Accumulated Expenses data on file, last reported at $12.0 million in Q4 2025.

• On a quarterly basis, Accumulated Expenses rose 20.24% year-over-year to $12.0 million in Q4 2025; TTM through Dec 2025 was $12.0 million, a 20.24% increase from a year earlier, with the FY2025 full-year figure at $12.0 million, up 20.24% from the prior year.
• Accumulated Expenses for Q4 2025 stood at $12.0 million, up from $10.7 million in the prior quarter.
• Over the last five years, Accumulated Expenses for RDHL reached as high as $25.4 million in Q1 2021 and fell as low as $4.0 million in Q2 2024.
• Historically, Accumulated Expenses has averaged $16.0 million across 5 years, with a median of $17.9 million in 2022.
• Across the five-year window, Accumulated Expenses plunged 74.42% in 2023 and surged 169.78% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $20.9 million in 2021, then retreated by 14.1% to $17.9 million in 2022, then plunged by 74.42% to $4.6 million in 2023, then soared by 117.62% to $10.0 million in 2024, then climbed by 20.24% to $12.0 million in 2025.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $12.0 million in Q4 2025, $10.7 million in Q2 2025, and $10.0 million in Q4 2024.